Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Goiter01:27

Goiter

Goiter refers to an abnormal enlargement of the thyroid gland that may appear as a diffuse goiter (uniform enlargement) or nodular (single or multiple nodules). Functionally, it is classified as nontoxic (normal/low hormone levels) or toxic (excess hormone production).PathophysiologyDiffuse thyroid enlargement typically results from prolonged stimulation by thyroid-stimulating hormone (TSH) or TSH-like agents, commonly seen in hypothyroidism or iodine deficiency. In contrast, in hyperthyroid...
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
Functions of Thyroid Hormones01:18

Functions of Thyroid Hormones

The thyroid hormone (TH) plays a pivotal role in the intricate orchestration of physiological processes, exerting profound effects on development, metabolism, and homeostasis throughout different life stages.
TH is indispensable for the normal development and maturation of the skeletal, muscular, and nervous systems during fetal and childhood growth. It facilitates bone mineral turnover and regulates protein synthesis in developing tissues, contributing significantly to overall growth and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic relevance and molecular correlates of Claudin-1 expression in pancreatic neuroendocrine tumors.

Human pathology·2026
Same author

Impact of the French ENDOCAN-COMETE Network on Overall Survival in Rare Adrenocortical Carcinomas.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Molecular taxonomy of pancreatic neuroendocrine tumors reveals BEND2-fusions-driven transcriptional plasticity and therapeutic vulnerabilities.

Cell reports. Medicine·2026
Same author

Potentially radiation-induced late toxicity after irradiation of pituitary adenoma, a retrospective dosimetric study.

Radiation oncology (London, England)·2025
Same author

Normal organ [<sup>68</sup>Ga]DOTATOC uptake during PRRT: challenging the assumption of stable background shaped by cold somatostatin analogues treatment.

European journal of nuclear medicine and molecular imaging·2025
Same author

French expert consensus statement on diagnosis and management of primary hyperparathyroidism.

Annales d'endocrinologie·2025
Same journal

Predictive analytics and risk stratification models in internal medicine: from risk scores to real-time machine learning.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in skin disease therapeutics: from drug discovery to personalized treatment pathways.

Presse medicale (Paris, France : 1983)·2026
Same journal

AI in clinical diagnostics in dermatology: applications, validation, and real-world use cases.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in medical research and publishing: progress, risks, and future perspectives.

Presse medicale (Paris, France : 1983)·2026
Same journal

Ethical, legal, and regulatory challenges in AI-based healthcare tools.

Presse medicale (Paris, France : 1983)·2026
Same journal

Decision-making for clinicians.

Presse medicale (Paris, France : 1983)·2026
See all related articles

Related Experiment Video

Updated: May 27, 2026

In vivo Characterization of Endocrine Disrupting Chemical Effects via Thyroid Hormone Action Indicator Mouse
04:14

In vivo Characterization of Endocrine Disrupting Chemical Effects via Thyroid Hormone Action Indicator Mouse

Published on: October 6, 2023

[Subclinical thyroid dysfunction].

Bernard Goichot1, Florina Luca

  • 1Hôpitaux universitaires de Strasbourg, service de médecine interne, endocrinologie et nutrition, hôpital de Hautepierre, 67098 Strasbourg cedex, France. bernard.goichot@chru-strasbourg.fr

Presse Medicale (Paris, France : 1983)
|November 26, 2011
PubMed
Summary
This summary is machine-generated.

Subclinical thyroid disease, characterized by abnormal thyrotropin (TSH) levels with normal thyroid hormones, poses long-term risks. Treatment may be considered for specific cases of subclinical hyperthyroidism and hypothyroidism, especially in older adults.

More Related Videos

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

Related Experiment Videos

Last Updated: May 27, 2026

In vivo Characterization of Endocrine Disrupting Chemical Effects via Thyroid Hormone Action Indicator Mouse
04:14

In vivo Characterization of Endocrine Disrupting Chemical Effects via Thyroid Hormone Action Indicator Mouse

Published on: October 6, 2023

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

Area of Science:

  • Endocrinology
  • Internal Medicine

Context:

  • Subclinical thyroid disease is defined by abnormal thyrotropin (TSH) levels with normal thyroid hormone concentrations.
  • These conditions are often asymptomatic but carry risks of long-term complications.

Purpose:

  • To review the risks and treatment indications for subclinical thyroid diseases.
  • To provide guidance on managing subclinical hyperthyroidism and hypothyroidism.

Summary:

  • Subclinical hyperthyroidism, particularly in those over 60, is linked to atrial fibrillation. Treatment with radioiodine may be considered for elderly patients with autonomous thyroid disease and persistently low TSH (<0.1 mU/L).
  • Subclinical hypothyroidism, especially in individuals under 60, can contribute to cardiovascular risk. Elevated TSH (>10 mU/L) and positive anti-TPO antibodies predict progression to overt hypothyroidism. Treatment in the elderly with moderately elevated TSH is generally not recommended.

Impact:

  • Highlights the importance of recognizing and managing subclinical thyroid dysfunction.
  • Informs clinical decision-making regarding treatment thresholds and patient selection for intervention.